How Human Resources Can Improve Biotech M&A Performance

Nov. 19, 2010, 5:00 AM UTC

Biopharma merger and acquisition activity has reignited in the past year, driven by the economic realities of pharmaceutical companies needing to evolve business models and biotechs hungry for capital infusions. In the first half of 2010 alone, there were 40 biopharma M&A deals totaling $80.5 billion.1Todd Davis and Gregory Brown, MD., “The New Normal,” The Deal Magazine, Sept. 2, 2010, see http://www.thedeal.com. Moreover, industry leaders expect increased action going forward. Looking at 2011, 87 percent of health care investors believed biopharma M&A deals would see a significant increase, with oncology predicted to be of greatest interest.2“Life Sciences and Healthcare Sector Forecast,” Remark, The Mergermarket Group, 2010.

Another trend that is driving increased M&A activity is an evolution from pharmas licensing biotech products to acquiring the company on terms that mirror a licensing deal. In this case, pharmas’ demand for pipeline fillers is greater than biotech supply, so sellers are using that leverage to insist on an acquisition that serves their need for an exit. Examples include Celgene’s acquisition of Abraxis and Novartis AG’s acquisition of Corthera.3Adam H. Golden and Joel I. Greenberg, “Drug of Choice,” The Deal Magazine; Aug. 13, 2010, see http://www.thedeal.com.

Given the increasingly critical role that M&As are playing in the industry, researching what can be done to optimize their success rate would be of great interest, particularly as these deals overall have low odds of success. Numerous studies show dismal statistics. For example, about 70 percent of mergers destroy shareholder value.4David Harding and Sam Rovit, Mastering the Merger: Four Critical Decisions that Make or Break the Deal, Boston: Harvard Business School Press, 2004. And an A.T. Kearney study found that “Only 15% of mergers and acquisitions in the U.S. achieve their financial objectives, as measured by share value, return on investment, and postcombination profitability.”5Charman (1999). A.T. Kearney study conducted in 1998 and reported in Habeck et al. (2000).

Biopharma deals also perform poorly—“Most observers agree that the pharmaceutical and biotech industry is no different from other industries in that most M&A transactions fail to create value for the acquiring company, although they generally do so for the target’s shareholders.”6“Executive Briefing—Strategic M&A Support for Pharmaceutical and Biotech Companies minimising the risk of ‘Winner’s Curse,’ ” Catenion, London, available at http://www.catenion.com/assets/executive-briefings/strategic-ma-support-for-pharma-biotech-companies.pdf. Indirect support for this high probability of failure derives from recent research showing that success rates for in-licensed compounds consistently are lower than for those developed in-house.7“Externally Sourced Compounds Are More Likely to Fail,” CMR International, Thomson Reuters, 2010.

HR—A Major Determinant of M&A Success

Are there controllable factors that affect the success of an M&A deal? Although controlled studies are impossible, a research evidence base examining significant variables correlated with success or failure has developed over the past several years. One of the factors consistently shown to be of critical importance to an M&A deal ultimately generating value is the involvement and capabilities of the human resources (“HR”) function. Almost every aspect of HR has been found crucial to the M&A process, and every stage of the process has been shown to benefit greatly from a “high powered” HR role.

Recent research from Towers Watson and the Canadian Financial Executives Research Foundation concluded, “Our research shows having a good track record in managing people issues in an M&A is a clear predictor of success in subsequent transactions. … In our study of finance executives, the very successful dealmakers involved their HR counterparts more often, and earlier in the transaction. … In tandem with HR’s increasing presence in all phases of a transaction, HR executives believe nontraditional abilities, such as cultural alignment and project management, are more important in an M&A context than traditional HR skills such as compensation and benefits design. Finance executives agree.” 8“Positioning for M&A Success: Putting People into the Equation,” Towers Watson, October 2009; and “People Issues in Mergers and Acquisitions: Learning from Experience.” Canadian Financial Executives Research Foundation and Towers Watson, September 2009, available at http://www.feicanada.org.

The literature is replete with conclusions linking HR to M&A success. David Kidd of Egon Zehnder International remarks, “Many mergers do not create the shareholder value expected of them. The combination of cultural differences and an ill-conceived human resource integration strategy is one of the most common reasons for that failure.”9D.A. Light, “Who goes, who stays?” Harvard Business Review, (January 2001) p. 39. Also, Laura Carlson, corporate finance lawyer at Faegre and Benson, says, “Employers now recognize that human resource issues are the primary indicator of the success or failure of a deal.”10S. Armour, “Merging Companies Act to keep valuable employees,” USA Today, Nov. 24, 2000, Section B. And a 2010 Towers Watson report states, “The companies in our study that rated their deals as successful involved HR earlier and more intensely in all phases of their M&A, from target identification (where HR can help assess cultural fit) to integration implementation (where HR can help to ensure the success of the new culture).”11“Creating deal success through people: Mastering M&A culture and integration issues.” Towers Watson, 2010.

A number of recommendations are offered by consultants, investors, acquirers, and academics regarding optimizing the HR M&A function and more broadly applying best practices to analyzing, protecting, and managing human capital. Three of the areas most commonly addressed are HR’s role in conducting due diligence, managing cultural issues, and integrating the organizations. Selected highlights from a literature review of how to improve the odds of M&A success using HR as a critical resource to meet these challenges are discussed below.

HR’s Role in Due Diligence

The Boston Consulting Group, along with other consulting firms, has distilled all M&A success factors down to just four, and one of these is HR’s involvement in due diligence.12“Growing Through Acquisitions,” The Boston Consulting Group, 2004. Furthermore, McIntyre points out, “In addition, literary findings show that the degree to which HRD [human resource development] is involved in due diligence correlates with the degree of integration and success of a given deal.”13Tammy L. McIntyre, “A Model of Levels of Involvement and Strategic Roles of Human Resource Development (HRD) Professionals as Facilitators of Due Diligence and the Integration Process,” Human Resource Development Review, June 2004, 3: 173-182, doi:10.1177/1534484304265444. Best practices dictate that HR take a leadership role in identifying risks in the target’s organizational structure, employees, and leadership, and culture. Identifying human capital risks serves a number of important functions. First, assessment of these risks goes directly to valuing the acquisition target and providing negotiation leverage. Secondly, early understanding of these risks enables HR to initiate integration planning pre-closing to minimize the acquisition’s liabilities and leverage key assets. Studies have shown that this early planning is an important factor in ultimate success.14“Where’s HR? Positioning Human Resources as a strategic due diligence partner,” Deloitte, 2009.

Prescriptives for HR’s assessment of organizational risks describe conducting both “hard,” data-driven and “soft,” interview-based analyses. Hard data should include, for example, organization charts, job descriptions, head counts, reporting lines, and decision process flowcharts. Employee interviews should supplement these analytics, and further delve into business unit functions, assets, capabilities, and deliverables track record. From this, HR should begin to settle on a design for the integrated company’s organizational structure, as well as the changes needed to get there.

Optimal HR due diligence also involves assessment of employment and personnel risks—for example, losing key talent, overall retention issues, and potential liabilities in employment programs. Employee retention risks are particularly important in biopharma deals in which knowledge transfer depends on keeping critical scientists, for example. Given that many employees depart immediately after an M&A deal closes, plans for retaining key people need to start pre-closing. One rule of thumb offered for a retention package is offering a bonus equal to one-half of a year’s salary for staying one year and tying the bonus to a deliverable during that year.15Kristen Donahue, “How to Ruin a Merger: Five People-Management Pitfalls to Avoid,” Harvard Management Update, September 2001.

Finally, best practices for HR due diligence encompass identifying risks associated with cultural fit. Many experts emphasize the need to invest time and HR resources in this cultural due diligence, as cultural issues reside so frequently at the core of failed acquisitions.16David Harding and Ted Rouse, “Human due diligence,” Harvard Business Review, April 2007. Indeed, some recommend that HR have a go/no go determination on pursuing the deal based on the outcome of the cultural fit analysis. HR’s involvement with culture throughout the M&A process is considered in the next section.

HR’s Role in Cultural Transition

The majority of literature reviewed found the meshing of cultures to be a primary determinant of M&A performance, and HR’s involvement and capabilities to be a major factor in the outcome. For example, an extensive survey by consulting firm Towers and Perrin found that 56 percent of respondents cited incompatibility of cultures as a major reason for failure to achieve desired synergies and objectives in their M&A deal.17“The role of human capital in M&A,” Towers Perrin, 2003.

It is valuable to define culture in this context to delineate the issues that need to be assessed and addressed. Schein’s definition includes three levels: 1) “Artefacts,” which describes visible organizational structures and processes, including physical, behavioral, and stories or myths; 2) “Values,” the social principles, goals, and standards; and 3) “Underlying assumptions,” implicit beliefs and habits.18E.H. Schein, “Coming to a new awareness of organizational culture,” Sloan Management Review, Winter 1984, Vol. 25, pp. 3-16.

The first step is analyzing the cultural fit during due diligence. Recommendations for early analysis of the target company’s culture include:19David Harding and Ted Rouse, “Human Due Diligence,” Harvard Business Review, April 2007.

  • generating a fundamental organizational fact base—job descriptions, organizational maps, compensation programs, employee surveys, 360 degree feedback reviews, turnover rates;


  • creating decision flowchart—how organizations make decisions;


  • assessing leadership and management styles—decision making, communication, receptiveness to change, planning;


  • conducting employee cultural surveys; and


  • seeking external views of company culture from customers, suppliers, etc.

A fundamental decision that needs to be made early on with HR’s direction is whether the merged entity will aim to preserve the two distinct cultures, create a new culture, or have one company adopt the other’s culture. Depending on the objective, HR must assess the degree to which cultural differences might lead to failed integration, regardless of change initiatives. Assuming the deal proceeds, HR needs to work with leadership to define the new values of the merged entity, and the behaviors that derive from those values, and to develop a plan for transitioning the organizations and leadership to that culture.

Companies that successfully addressed culture during M&A also consistently made time to bring senior leaders together to delve into the similarities and differences in their ways of working and what actions might need to be taken as a result. Further, these leaders identified specific, value-generating behaviors that would be key to successfully merging the companies and prioritized explicit levers that reinforced those behaviors. Finally, systems were established for tracking the progress of the cultural alignment, often using leading indicators to monitor success or failure on an ongoing basis.20“POV: Capitalizing on Culture—Leading companies share what it takes,” Mercer, Nov. 20, 2009.

HR’s Role in Organizational Integration

The final key HR performance determinant concerns organizational integration, of which a major component is cultural assimilation. A wide variety of functions and best practices are encompassed by HR’s role in the integration stage. A few of the evidence-based recommendations supported by multiple reports include:

  • Rapid integration—studies show that there is direct correlation between speed of integration and M&A success.21“The role of human capital in M&A,” Towers Perrin, 2003.


  • Rapid (within the first 12 months) integration of biopharma sales forces also is critical. Form a dedicated “revenue momentum” team to facilitate transition and minimize disruption.22Gerald Adolph, Bob Hutchens, and Justin Pettit, “Capability-Driven PMI: Realising the Promise of BioPharma,” Booz & Co., June 9, 2010, available at http://executiveview.com/knowledge_centre.php?id=11688.


  • Implementation of job cuts quickly and in very few passes, to mitigate demoralization and anxiety.23“The role of human capital in M&A,” Towers Perrin, 2003.


  • Creation of a transformation roadmap with multiyear targets and measurable progress systems.


  • Development of extensive communication programs for leadership and HR to employ regularly throughout the companies during integration. Explain why the deal is good for employees and discuss future job security.


  • Involve employees—“Staff involvement serves as a guarantee of cooperation and support for the immediate post-merger phase. Staff involvement includes exchanging ideas, concerns, proposals, and feedbacks.”24Steven H. Appelbaum, Frederic Lefrancois, Roberto Tonna, and Barbara T. Shapiro, “Mergers 101 (part one): training managers for communications and leadership challenges,” Industrial and Commercial Training, (2007) Vol. 39, Issue 3, pp. 128–136.

A number of studies have developed HR integration best practices specifically for biopharma M&A, based on the business objectives, assets, and cultural issues that characterize this industry.

For example, Booz’s “capability-driven” integration is based on the view that “BioPharma integrations are more about capability-building. This creates two types of strategic intent challenges—adding a capability to a large organisation (“how do we keep from just swallowing them”) and, infusing a new capability throughout a large organisation (“how can they be a catalyst to change us”).” HR’s charge then becomes to develop an operating model that centers around a core set of critical capabilities and to direct plans to build scale in these targeted capabilities.25Gerald Adolph, Bob Hutchens, and Justin Pettit, “Capability-Driven PMI: Realising the Promise of BioPharma,” Booz & Co., June 9, 2010, available at http://executiveview.com/knowledge_centre.php?id=11688.

Finally, Schweizer researched organizational integration issues following pharma acquisitions of biotech companies.26Lars Schweizer, “Post-acquisition integration of small biotechnology firms in the structure of large pharmaceutical companies,” Erscheinungsjahr an der Haupttitelstelle: 2001, Bamberg, Univ., Dissert., 2002. He found that pharmaceutical companies usually differed in their approaches to integrating non-R&D versus R&D functions in terms of the degree, timing, and speed of integration. Schweizer’s work concluded with a proposal for a new, hybrid framework for integrating acquired biotechs, one best implemented by HR. The first step identifies the biotech’s core capabilities along the value chain. Capabilities in the early half of the value chain (“left side”), such as discovery and development, are knowledge-intensive and highly innovative and thus considered dependent on a biotech culture. Capabilities in the other half (“right side”), such as regulatory and sales and marketing, are considered more operational and not dependent on a biotech culture.

The proposed scheme recommends a dual-path, parallel integration program wherein left-side functions (typically, R&D) are given autonomy and integrated very slowly with attempts to preserve aspects of the biotech culture, while right-side functions are absorbed into the pharmaceutical organization rapidly. Schweizer explains the objective: “Preserving the innovative capability of the biotechnology company has been one of the dominant motives for the acquisition. By this, they are to contribute to the long-term growth of the pharmaceutical company. Thus, the overall organizational integration strategy must be to grant the acquired biotechnology company as much autonomy and independence as possible. Because of this, a slow integration process is the right alternative to choose.”27Id.

Final Thoughts

With M&A’s track record of more failures than successes and HR’s evidence base of performance improvements, one would surmise that corporations would be widely adopting an extensive, structured role for HR in the M&A process. Surprisingly, though, studies do not indicate that a majority of acquirers are utilizing HR in the ways suggested by the research reviewed here. “The most common responsibility given to HR (and the only one to be identified by a majority of respondents) is to provide ad hoc advice to senior managers. In other words, the majority of HR departments do not have a structured and formal role to play in their companies’ M&A activity.”28“The role of human capital in M&A,” Towers Perrin, 2003

Perhaps there’s a disconnect between what’s conceived of as “soft” people issues and “hard,” quantitative, fact-based transactions. “No one would dispute the importance of people and culture issues in a merger, or the value of an effective, engaged, and well-integrated workforce in a new organization’s success. But the simple fact is, even today, people- and culture-related issues—things such as effectively and openly communicating with employees throughout the transition, creating and implementing strategies to retain key employees, and focusing on cultural alignment between unfamiliar organizations—still don’t command the same level of rigor and focus that financial or operational issues do.”29“Creating deal success through people: Mastering M&A culture and integration issues,” Towers Watson, 2010.

Here, then, is a great opportunity for competitive differentiation. The research strongly suggests that by giving HR the resources, responsibility, and time to take a central and early role on the M&A team, your organization can significantly improve the performance of your next acquisition, and thus advance your competitive position in the marketplace.

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.